Abstract 13485: Impact of Low Dose Atorvastatin on Development of New-onset Diabetes Mellitus in Asian Population: Five-year Clinical Outcomes
Background: High dose atrovastatin is known to be associated with new onset diabetes mellitus (DM) in patients (pts). However, there have been limited data whether low dose atrovastatin can be associated with increased incidence of new-onset DM. We investigated the impact of low dose (10mg or 20mg) atorvastatin on the development of new-onset DM based on five-year clinical outcomes in Asian patients.
Methods: We investigated a total of 3,566 consecutive patients (pts) who did not have DM from January 2004 to September 2009. To adjust potential confounders, a propensity score matched (PSM) analysis was performed using the logistic regression model. The primary end-point was the cumulative incidence of new-onset DM which was defined as having a fasting blood glucose ≥126 or HbA1c ≥6.5%. and assessed to determine the impact of low dose atrovastatin (10mg or 20mg).
Results: Mean follow-up duration was 976±278 days in all-pt group, and 993±240 days in PSM group. After PSM (C-statistics: 0.851), a total 818 pts (low dose atrovastatin group=409 and control group = 409) were enrolled for analysis. Adjusted with cox-regression analysis showed that low dose atorvastatin was a significant independent predictor of new-onset DM (OR=1.99, 95%CI 1.00- 3.98, p=0.050, figure A). After PSM analysis, total 98 pts (atorvastatin 10mg, 49 and 20mg, 40) were analyzed (C-statistics: 0.715). There was no difference in the cumulative incidence of new-onset DM between the two groups (figure B).
Conclusions: Low dose atorvastatin therapy was associated with the cumulative incidence of new-onset DM, however, there was no difference between atrovastatin 10mg and 20mg in Asian population.
- © 2013 by American Heart Association, Inc.